Ionis Announces Webcast to Present Results of HALOS Study for ION582 in Angelman Syndrome

Webcast planned for Monday July 22 has 8:00 AM Eastern Time

CARLSBAD, California, July 8, 2024 /PRNewswire/ –Ionis Pharmaceuticals, Inc., (NASDAQ: IONS) today announced that it will host a live webcast on Monday July 22^nd has 8:00 AM Eastern Time to discuss results from the Phase 1/2a HALOS study of ION582 for the treatment of people with Angelman syndrome. Results from the HALOS study will also be presented on Wednesday July 24 at the Angelman Syndrome Foundation (ASF) 2024 Family Conference and Research Symposium in Sandusky, Ohio.

The webcast can be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.

About Ionis Pharmaceuticals, Inc.
For three decades, Ionis has been inventing medicines that provide a brighter future for people with serious diseases. Ionis currently has five medicines on the market and a leading pipeline in neurology, cardiology and other areas of high patient need. As a pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA-based therapeutics and advance new approaches in gene editing. A deep understanding of disease biology and cutting-edge technology drive our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) and LinkedIn.

Ionis Pharmaceuticals Investor Contact:
D. Wade WalkePh.D. – [email protected] – 760-603-2331

Ionis Pharmaceuticals Media Contact:

Hayley Soffer – [email protected] – 760-603-4679

View original content to download multimedia: https://www.prnewswire.com/news-releases/ionis-announces-webcast-to-announce-halos-study-results-for-ion582-in-angelman-syndrome-302189257.html

SOURCE Ionis Pharmaceuticals, Inc.